Loading…
MIGRALEVE is a brand name for Buclizine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the short-term treatment of acute moderate pain which is not relieved by paracetamol, ibuprofen or aspirin alone such as migraine attacks including the symptoms of migraine headache, nausea and vomiting. Codeine is indicated in children older than 12 years of age for the treatment of acute moderate pain which is…
Verbatim from this product's MHRA label. Tap a section to expand.
Route of administration – oral. 4). P only The duration of treatment should be limited to 3 days and if no effective pain relief is achieved the patients/carers should be advised to seek the views of a physician.
POM and P Adults and Children 16 years and over:
Two Migraleve Pink tablets to be swallowed immediately it is known that a migraine attack has started or is imminent. If further treatment is required, two Migraleve Yellow tablets every 4 hours. Maximum dose: 8 tablets (two Migraleve Pink and six Migraleve Yellow) in 24 hours.
Children 12 – 15 years:
One Migraleve Pink tablet to be swallowed immediately it is known that a migraine attack has started or is imminent. If further treatment is required, one Migraleve Yellow tablet every 4 hours. Maximum dose: 4 tablets (one Migraleve Pink and three Migraleve Yellow) in 24 hours.
4).
Regular prolonged use of codeine is known to lead to addiction and symptoms of restlessness and irritability may result when treatment is stopped. Prolonged use of a painkiller for headaches can make them worse. Very rare cases of serious skin reactions have been reported with paracetamol.
Adverse drug reactions (ADRs) identified during clinical trials and post- marketing experience with paracetamol, codeine, buclizine hydrochloride, or the combinations of paracetamol/codeine or paracetamol/codeine/buclizine hydrochloride are listed below by System Organ Class (SOC).
The frequencies are defined according to the following convention:
Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1,000 and <1/100); Rare (≥1/10,000 and <1/1,000); Very rare (<1/10,000), Not known (cannot be estimated from the available data). ADRs are presented by frequency category based on 1) incidence in adequately designed clinical trials or epidemiology studies, if available, or 2) when incidence is unavailable, frequency category is listed as ‘Not known’.
4) Very common Headache5,6 Very Common Somnolence1,2,5 Common Dizziness1,2,5,6 Nervous system disorders Not known Psychomotor skills impaired5 Eye disorders Not known Vision blurred5 Vascular disorders Very common Flushing6 Not known Bronchospasm2 Respiratory, thoracic and mediastinal disorders Not known Dyspnoea6 Not known Increased viscosity of bronchial secretion5 Not known Respiratory depression2 Very common Nausea1,2 Common Constipation1,2 Common Dry mouth1,2,5 Common Vomiting1,2 Not known Abdominal pain6 Not known Dyspepsia2 Not known Gastrointestinal disorder5 Gastrointestinal disorders Not known Pancreatitis acute2 (in patients with a history of cholecystectomy) Hepatobiliary disorders Not known Liver injury3,8 Common Hyperhidrosis1,2 Uncommon Rash3,5 Not known Angioedema5,6 Not known Dermatitis2 Not known Erythema5 Not known Fixed eruption3 Not known Pruritus2,6 Skin and subcutaneous tissue disorders Not known Urticaria2,3,5 Not known Dysuria2,5 Renal and urinary disorders Not known Nephropathy toxic3 General disorders and administration site conditions Uncommon Drug withdrawal syndrome2 Investigations Not known Transaminases increased7 Metabolism and nutrition disorders Not known High anion gap metabolic acidosis 1Adverse events reported by ≥1% of codeine/paracetamol treated subjects in 27 randomised placebo-controlled trials 2Associated with codeine 3Associated with paracetamol 4Reported following paracetamol use, but not necessarily causally related to the drug 5 Associated with buclizine 6Associated with paracetamol / codeine combination 7Low level transaminase elevations may occur in some patients taking therapeutic doses of paracetamol; these elevations are not accompanied with liver failure and usually resolve with continued therapy or discontinuation of paracetamol.
Migraine should be medically diagnosed. Migraleve tablets are intended for short-term use only. Migraleve tablets contain potent medicaments and should not be taken continuously for extended periods without the advice of a doctor. Codeine Codeine is an opioid agent.
8). Codeine may cause addiction if taken continuously for more than three days. POM only Drug dependence, tolerance and potential for abuse For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses.
, major depression). Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse. A comprehensive patient history should be taken to document concomitant medications, including over the-counter medicines and medicines obtained on- line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers.
These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient. Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction. The clinical need for analgesic treatment should be reviewed regularly. Drug withdrawal syndrome Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with codeine.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
1. 4). Head injury; in conditions in which intracranial pressure is increased; acute respiratory depression; obstructive bowel disorders and in patients at risk of paralytic ileus. 6). In patients for whom it is known they are CYP2D6 ultra-rapid metabolisers.
Migraleve tablets are contraindicated for children below 12 years of age.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Buclizine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
8Chronic hepatic necrosis has been reported in a patient who took daily therapeutic doses of paracetamol for about a year. Other known ADRs that occur with codeine include: anorexia, antidiuretic effect, hypothermia, malaise, muscle fasciculation, and seizures.
Adverse drug reactions (codeine class effects) include: • Sedation • Vertigo • Bronchospasm • Gastrointestinal disorder, such as dyspepsia, nausea, vomiting, constipation • Euphoric mood • Drug dependence can develop following long-term use of high doses • Adrenal insufficiency (long term use) • Hypogonadism High anion gap metabolic acidosis.
4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome. Hyperalgesia Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.
This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality.
Symptoms of hyperalgesia may resolve with a reduction of opioid dose. POM and P Codeine should be used with caution in patients with convulsive disorders, decreased respiratory reserve, such as bronchial asthma, pulmonary oedema and obstructive airways disease.
5). Administration of pethidine and possibly other opioids analgesics to patients taking a monoamine oxidase inhibitor (MAOI) has been associated with very severe and sometimes fatal reactions. 5). Codeine should be used with caution in patients with renal or hepatic impairment.
If codeine is taken for headaches for more than 3 days it can make them worse (medication overuse headaches). The risk-benefit of continued use should be assessed regularly by the prescriber. Opioids have also been associated with: • Adrenal insufficiency (long term use).
• Hypogonadism. • Prostatic hypertrophy and urethral stenosis (in adults). CYP2D6 metabolism Codeine is metabolised by the liver enzyme CYP2D6 into morphine, its active metabolite. If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect will not be obtained.
Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an extensive or ultra-rapid metaboliser there is an increased risk of developing side effects of opioid toxicity even at commonly prescribed doses.
These patients convert codeine into morphine rapidly resulting in higher than expected serum morphine levels. General symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation and lack of appetite.
In severe cases this may include symptoms of circulatory and respiratory depression which may be life-threatening and very rarely fatal. 9% Northern European 1%-2% When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose.
Use of the drug should be discontinued and immediate medical advice sought at […]